MedTrace Logo

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

NCT00002715 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-08-12

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

Bleomycin sulfate

A component of the Stanford V regimen.

DRUG

Stanford V regimen

DRUG

Doxorubicin hydrochloride

A component of the Stanford V regimen.

DRUG

Etoposide

A component of the Stanford V regimen.

DRUG

Mechlorethamine hydrochloride

A component of the Stanford V regimen.

DRUG

Prednisone

A component of the Stanford V regimen.

DRUG

Vinblastine

A component of the Stanford V regimen.

DRUG

Vincristine sulfate

A component of the Stanford V regimen.

Sponsors & Collaborators

Principal Investigators

  • Sandra J. Horning, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1989-04-30
Primary Completion
2007-01-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002715 on ClinicalTrials.gov